Status:
COMPLETED
iCAT for Recurrent/Refractory/HR Solid Tumors
Lead Sponsor:
Dana-Farber Cancer Institute
Conditions:
Pediatric Solid Tumor
Sarcoma
Eligibility:
All Genders
Up to 30 years
Brief Summary
In this study tumor will be tested for cancer causing gene alterations such as mutations or copy number alterations. This is called tumor profiling. A panel of experts will review the tumor profiling ...
Detailed Description
Some cancer-causing gene alterations (such as mutations or copy number alterations) are common or occur repeatedly in different types of cancers. For some of these alterations there are drugs, called ...
Eligibility Criteria
Inclusion
- Diagnosis of recurrent, refractory of high risk pediatric solid tumor (excluding brain tumor)
- Histologic proof of malignancy at the time of diagnosis or recurrence
- Sufficient tumor specimen available for profiling from diagnosis or recurrence, or surgery/biopsy planned for clinical care
Exclusion
- Brain tumors
Key Trial Info
Start Date :
August 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT01853345
Start Date
August 1 2012
Last Update
February 10 2015
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94143
2
Children's National Medical center
Washington D.C., District of Columbia, United States, 20010
3
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
4
Boston Children's Hospital
Boston, Massachusetts, United States, 02215